Lenox Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lenox Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1K	Hold	5	–	–	﹤0.01%	714
2021 Q4	$1K	Hold	5	–	–	﹤0.01%	857
2021 Q3	$1K	Hold	5	–	–	﹤0.01%	678
2021 Q2	$1K	Buy	+5	New	+$866	﹤0.01%	670
2020 Q2	–	Sell	-38	Closed	-$4K	–	693
2020 Q1	$4K	Buy	38 +23	+153%	+$2.97K	﹤0.01%	455
2019 Q4	$2K	Hold	15	–	–	﹤0.01%	608
2019 Q3	$2K	Buy	+15	New	+$2.01K	﹤0.01%	507
2019 Q2	–	Sell	-13	Closed	-$2K	–	497
2019 Q1	$2K	Buy	+13	New	+$1.7K	﹤0.01%	532

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Lenox Wealth Advisors's JAZZ Position: Q1 2022 in Review

Lenox Wealth Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2022 at 5 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #714.

Lenox Wealth Advisors first reported a position in JAZZ in Q1 2019 and has held it in 8 quarters since. The position peaked at $4K in Q1 2020. 461 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Lenox Wealth Advisors held 5 shares of Jazz Pharmaceuticals worth $1K as of Q1 2022.
Lenox Wealth Advisors left its Jazz Pharmaceuticals share count unchanged in Q1 2022.
Jazz Pharmaceuticals made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #714 holding.
Lenox Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 8 quarters since.
Lenox Wealth Advisors's Jazz Pharmaceuticals position peaked at $4K in Q1 2020.
461 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.